STOCKHOLM, Aug 31 (Reuters) - An experimental drug from Bristol-Myers Squibb (BMY.N) and Pfizer (PFE.N) reduces the risk of stroke by more than half compared with aspirin, with no significant rise in major bleeding, researchers said on Tuesday.
STOCKHOLM, Aug 31 (Reuters) - An experimental drug from Bristol-Myers Squibb (BMY.N) and Pfizer (PFE.N) reduces the risk of stroke by more than half compared with aspirin, with no significant rise in major bleeding, researchers said on Tuesday.